文献速递前列腺癌男科与性医学

雄激素剥夺治疗三种方案的患者偏好:焦点小组研究

Preferences between three options for androgen deprivation therapy: a focus group study.
PubMed 文献 · BJU Int · 2025-07-30

本研究通过五个焦点小组、共24名英国男性(10名无前列腺癌史、14名早期前列腺癌未接受ADT)探讨ADT选择偏好;多数人倾向避免LHRH激动剂注射,14人选择口服LHRH拮抗剂、8人选择tE2贴片、2人选择LHRH激动剂注射。

要点

  • 患者认为ADT治疗选择权重要,参与决策有助于维持控制感
  • 24人中14人选择口服LHRH拮抗剂,8人选择tE2贴片,2人选择LHRH激动剂注射
  • 偏好受副作用、后勤因素和信任者建议影响,并受既往经历与健康信念调节

核心结论

  • 男性希望有ADT选择权,若存在其他ADT选项,许多人不愿选择LHRH激动剂注射。

研究设计与样本

  • 五个焦点小组,共24名来自英国各地的男性参与,其中10人从未患前列腺癌、14人患早期前列腺癌但未接受ADT。
  • 焦点小组由患者与公众参与代表共同主持,转录稿采用批判实在主义主题分析法分析。

主要发现

  • 参与者报告拥有ADT选择权很重要,参与治疗决策可帮助男性维持控制感。
  • 多数男性表示偏好避免LHRH激动剂注射ADT;24人中14人选择口服LHRH拮抗剂,8人选择tE2贴片,2人选择LHRH激动剂注射。
  • 影响治疗选择的因素归为三类:治疗副作用、后勤方面、信任者的建议。
  • 个人偏好基于参与者认为重要的因素,其优先级受既往经历、当前健康信念和未来期望影响。

临床怎么用

  • 报销委员会和指南制定者在考虑替代ADT策略的作用时,应考虑男性对ADT选择权的偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone-releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists. This study aimed to identify whether this is an important choice for men, which treatment men would choose if offered either LHRH agonist injections, tE2 patches or oral LHRH antagonists as ADT, and to explore the factors influencing this decision. SUBJECTS, PATIENTS, AND METHODS: Five focus groups were conducted. A total of 24 men from around the UK participated in discussions, of whom 10 had never had prostate cancer and 14 had early prostate cancer but had not received ADT. Focus groups were co-facilitated with patient and public involvement representatives. Transcripts were analysed using a critical realist thematic analysis approach. RESULTS: Participants reported that having a choice of ADT is important and being involved in making treatment decisions can help men maintain an element of control. Most men expressed a preference to avoid ADT with LHRH agonist injections; 14 of the 24 men reported they would choose an oral LHRH antagonist, eight reported they would choose tE2 patches, and two that they would choose LHRH agonist injections. Participants reported a large number of factors that influenced their treatment choice that were grouped into: (i) side-effects of treatment, (ii) logistical aspects, and (iii) advice from trusted others. Personal preferences between different types of ADT were based on factors that participants identified as important to them, this prioritisation of factors was influenced by participants' past experiences, current health beliefs, and future expectations. CONCLUSIONS: Men wish to have choice of ADT, and many would not choose LHRH agonists injections if there were other ADT options available. This should be considered, as reimbursement committees and guideline-makers consider the role of alternative ADT strategies.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Rush HL, Merrick S, Marshall J, et al. Preferences between three options for androgen deprivation therapy: a focus group study. BJU Int. 2025. PMID: 40739874. doi:10.1111/bju.16863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。